ATLANTA, Aug. 31, 2017 -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, President and Chief Financial Officer, will present at the 19th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017 at the Lotte New York Palace Hotel, New York, New York. Alimera Sciences’ presentation will take place Tuesday, September 12th, 2017 at 3:00pm Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early-and late-stage diseases. For more information, please visit www.alimerasciences.com.
For press inquiries: Katie Brazel for Alimera Sciences 404-317-8361 [email protected] For investor inquiries: CG Capital for Alimera Sciences 877-889-1972 [email protected]


Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 



